Stock data
AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. (ABCL) reported revenue of US$75.13M and net income of -US$146.41M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$75.13M | — | -US$217.10M | -US$146.41M | — |
| 2024 | US$28.83M | — | -US$314.77M | -US$162.86M | — |
| 2023 | US$38.02M | — | -US$237.21M | -US$146.40M | — |
| 2022 | US$485.42M | — | US$216.51M | US$158.52M | — |
| 2021 | US$375.20M | — | US$204.41M | US$153.46M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$4.05M | -US$55.43M | — |
| 2026-03-31 | US$8.31M | -US$43.16M | — |
| 2025-12-31 | US$44.85M | -US$8.95M | — |
| 2025-09-30 | US$8.96M | -US$57.12M | — |
| 2025-06-30 | US$17.08M | -US$34.73M | — |
| 2025-03-31 | US$4.24M | -US$45.62M | — |
| 2024-12-31 | US$5.05M | -US$34.21M | — |
| 2024-09-30 | US$6.51M | -US$51.11M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.